Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy

This publication has 99 references indexed in Scilit:

• Bcl-2 pathway inhibition in solid tumors: a review of clinical trials
  Clinical and Translational Oncology, 2023
• An acylhydroquinone derivative produces OXPHOS uncoupling and sensitization to BH3 mimetic ABT-199 (Venetoclax) in human promyelocytic leukemia cells
  Bioorganic Chemistry, 2020
• Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
  Cancer Cell, 2019
• Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
  American Journal of Hematology, 2018
• The emerging role and targetability of the TCA cycle in cancer metabolism
  Protein & Cell, 2017
• Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors
  Bioorganic & Medicinal Chemistry Letters, 2009
• Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program
  Pediatric Blood & Cancer, 2007
• BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents
  Cancer Cell, 2007
• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
  Cancer Cell, 2006
• Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
  Cancer Cell, 2006